Tag: Michel Demaré
Executive pay debate intensifies with proxy advisors in the firing line
Big pharma chair Michel Demaré points to proxy advisors as cause of block on higher pay while more FTSE 100 companies plan boost to packages.
AstraZeneca announces chair succession
Michel Demaré has been appointed chair-designate and will take over from Leif Johansson, who retires in April next year.